Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer

• Status: Active, not recruiting
• Trial end date: 2022-02-02
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase II, open-label, single arm, single-stage study. Both, chemo-sensitive and chemo-resistant patients will be enrolled and treated with 4 cycles of combination of Guadecitabine and carboplatin

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shadia Jalal, MD
• Collaborators: Astex Pharmaceuticals; Astex Pharmaceuticals, Inc.; Indiana University School of Medicine
• Treatments: Azacitidine; Carboplatin; Guadecitabine

Criteria

Inclusion Criteria:

• Male or female subjects, age ≥ 18 years.

• Histological or cytological diagnosis of small cell lung cancer. Subjects must have extensive-stage disease is defined as disease beyond the ipsilateral hemithorax, mediastinum and ipsilateral supraclavicular area and including malignant pleural or pericardial effusion or hematogenous metastases.

• Patient should not have received more than 1 prior line of chemotherapy (could have received immunotherapy which does not count as chemotherapy).

• ECOG PS 0-1

• Measurable disease as per RECIST v1.1. Subjects may have bone-only disease. NOTE:

Bone-only subjects are eligible if their disease can be documented/evaluated by bone scans, CT or MRI. Their disease will be assessed using MD Anderson criteria. NOTE: Previously irradiated lesions are eligible as a target lesion only if there is documented progression of the lesion after irradiation.

• Adequate bone marrow, liver, and renal function, as assessed by the following laboratory requirements:

• Hemoglobin ≥ 9.0 g/dL

• Absolute neutrophil count (ANC) ≥ 1,500/mm3

• Platelet count ≥ 100,000/mm3

• Total bilirubin ≤ 1.5 x upper limit of normal (ULN). For subjects with Gilbert's Disease, total bilirubin ≤ 3 x ULN

• ALT and AST ≤ 2.5 x ULN. For subjects with documented liver metastases, ALT and AST ≤ 5×ULN

• International Normalized Ratio (INR) ≤1.5, if not therapeutically anticoagulated. Subjects who are being therapeutically anticoagulated may be included provided that the anticoagulation regimen is stable and closely monitored.

• Estimated glomerular filtration rate (eGFR) ≥ 60 mL/minute/1.73 m2 as determined using the Cockcroft-Gault formula.

• Women of child-bearing potential must not be pregnant or breastfeeding and must have a negative pregnancy test at screening.

• Male and female subjects of child- bearing potential must agree to use an effective method of birth control from the screening visit through 6 months after the last dose of study drug.

Exclusion Criteria:

• Platinum refractory disease defined as disease progression during first line platinum containing chemotherapy regimen. Progression following platinum based therapy is allowed.

• Prior therapy with a hypomethylating agent.

• Previously untreated (non-irradiated), symptomatic brain metastases. No prior treatment is required for non-symptomatic brain metastases. Previously treated symptomatic brain metastases are permitted.

• Unstable or clinically significant concurrent medical condition, psychiatric illness or social situation that would, in the opinion of the investigator, jeopardize the safety of a subject and/or their compliance with the protocol.

• Clinically significant acute infection requiring systemic antibacterial, antifungal, or antiviral therapy. (Suppressive therapy for chronic infections allowed, for example: Subjects with HIV/AIDS with adequate antiviral therapy to control viral load would be allowed. Subjects with viral hepatitis with controlled viral load would be allowed while on suppressive antiviral therapy.)

• Hypersensitivity to (IMP) or components of the study treatment regimen.

• Treated with any investigational drug within 3 weeks of first dose of study treatment.

• Pregnant or breastfeeding.

• Second malignancy currently requiring active therapy except breast or prostate cancer stable on or responding to endocrine therapy.